{
  "id": "mhgap#risk_safety_0a6af71d",
  "content": "in decision-making;\ny methylphenidate prescription is made by, or in consultation with,\na specialist.\nStrength of recommendation: Conditional\nCertainty of evidence: Low\nJustification Remarks\ny Data were extracted from a systematic review: y Methylphenidate treatment should be offered\nCortese et al., 2018 (133 RCTs; 81 in children and only in the context of a management plan that\nadolescents, 51 in adults, and 1 in both) (51). address psychosocial risks and vulnerabilities\ny Methylphenidate treatment shows substantial and environmental factors that have an impact on\neffects on symptom reduction when compared with symptoms, functioning, well-being and participation\nplacebo and has lower certainty of evidence for less of children and adolescents with ADHD.\nsubstantial effects on school functioning in children y Methylphenidate treatment should be combined\n6 years and older and adolescents. when possible with brief parent behavioural\ny Methylphenidate prescription should be issued by, therapies.\nor in consultation with, a specialist, as substantial y Children and adolescents receiving methylphenidate\nweight loss is reported in children and adolescents should be maintained under close clinical\non methylphenidate treatment. monitoring for improvement in symptoms and\ny There is limited evidence on efficacy and tolerability prevention of adverse effects.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "emotions",
      "risk_safety",
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety in decision-making;\ny methylphenidate prescription is made by, or in consultation with,\na specialist.\nStrength of recommendation: Conditional\nCertainty of evidence: Low\nJustification Remarks\ny Data were extracted from a systematic review: y Methylphenidate treatment should be offered\nCortese et al., 2018 (133 RCTs; 81 in children and only in the context of a management plan that\nadolescents, 51 in adults, and 1 in both) (51). address psychosocial risks and vulnerabilities\ny Methylphenidate treatment shows substantial and environmental factors that have an impact on\neffects on symptom reduction when compared with symptoms, functioning, well-being and participation\nplacebo and has lower certainty of evidence for less of children and adolescents with ADHD.\nsubstantial effects on school functioning in children y Methylphenidate treatment should be combined\n6 years and older and adolescents. when possible with brief parent behavioural\ny Methylphenidate prescription should be issued by, therapies.\nor in consultation with, a specialist, as substantial y Children and adolescents receiving methylphenidate\nweight loss is reported in children and adolescents should be maintained under close clinical\non methylphenidate treatment. monitoring for improvement in symptoms and\ny There is limited evidence on efficacy and tolerability prevention of adverse effects. In decision-making;\ny methylphenidate prescription is made by, or in consultation with,\na specialist. strength of recommendation: conditional\ncertainty of evidence: low\njustification remarks\ny data were extracted from a ..."
}